TY - JOUR
T1 - Leaflet manual of external beam radiation therapy for hepatocellular carcinoma
T2 - A review of the indications, evidences, and clinical trials
AU - Rim, Chai Hong
AU - Yoon, Won Sup
N1 - Publisher Copyright:
© 2018 Rim and Yoon.
Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 2018/5/16
Y1 - 2018/5/16
N2 - The use of external beam radiation therapy (EBRT) in the treatment of hepatocellular carcinoma (HCC), which was rarely performed due to liver toxicity with a previous technique, has increased. Palliation of portal vein thrombosis, supplementation for insufficient transarterial chemoembolization, and provision of new curative opportunities using stereotactic body radiotherapy are the potential indications for use of EBRT. The mechanism of EBRT treatment, with its radiobiological and physical perspectives, differs from those of conventional medical treatment or surgery. Therefore, understanding the effects of EBRT may be unfamiliar to physicians other than radiation oncologists, especially in the field of HCC, where EBRT has recently begun to be applied. The first objective of this review was to concisely explain the indications for use of EBRT for HCC for all physicians treating HCC. Therefore, this review focuses on the therapeutic outcomes rather than the detailed biological and physical background. We also reviewed recent clinical trials that may extend the indications for use of EBRT. Finally, we reviewed the current clinical practice guidelines for the treatment of HCC and discuss the current recommendations and future perspectives.
AB - The use of external beam radiation therapy (EBRT) in the treatment of hepatocellular carcinoma (HCC), which was rarely performed due to liver toxicity with a previous technique, has increased. Palliation of portal vein thrombosis, supplementation for insufficient transarterial chemoembolization, and provision of new curative opportunities using stereotactic body radiotherapy are the potential indications for use of EBRT. The mechanism of EBRT treatment, with its radiobiological and physical perspectives, differs from those of conventional medical treatment or surgery. Therefore, understanding the effects of EBRT may be unfamiliar to physicians other than radiation oncologists, especially in the field of HCC, where EBRT has recently begun to be applied. The first objective of this review was to concisely explain the indications for use of EBRT for HCC for all physicians treating HCC. Therefore, this review focuses on the therapeutic outcomes rather than the detailed biological and physical background. We also reviewed recent clinical trials that may extend the indications for use of EBRT. Finally, we reviewed the current clinical practice guidelines for the treatment of HCC and discuss the current recommendations and future perspectives.
KW - Clinical trials
KW - External beam radiotherapy
KW - Guidelines
KW - Hepatocellular carcinoma
KW - Liver neoplasm
KW - Sorafenib
KW - Stereotactic body radiotherapy
UR - http://www.scopus.com/inward/record.url?scp=85047763997&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047763997&partnerID=8YFLogxK
U2 - 10.2147/OTT.S164651
DO - 10.2147/OTT.S164651
M3 - Review article
AN - SCOPUS:85047763997
VL - 11
SP - 2865
EP - 2874
JO - OncoTargets and Therapy
JF - OncoTargets and Therapy
SN - 1178-6930
ER -